《Commercial Times》
- 網頁服務 安克
- Apr 4
- 1 min read
Updated: Oct 30
AmCad and Swiss Team Share Study Outcomes at ISSS 2024: Ultrasound-AI Predicts HNS Response
Dr. Kurt Tschopp of Kantonsspital Baselland in Switzerland and AmCad BioMed presented the results of their study at the International Surgical Sleep Society Annual Meeting in Australia.
AmCad BioMed has partnered with Dr. Tschopp to use its ultrasound AI technology to predict the effectiveness of hypoglossal nerve stimulation therapy for obstructive sleep apnea (OSA). AmCAD-UO analyzes upper airway tissue structure to predict responsiveness to the hypoglossal nerve stimulator with predictive value as high as 80%, potentially saving costs and improving treatment outcomes.